Two years after originally announcing it, Medtronic and IBM Watson have launched their joint platform the Sugar.IQ, a digital diabetes assistant. "It is designed for people who are currently using Guardian Connect; so made for people on multiple daily injections. It is a personal assistant a little bit like Alexa or Siri," Huzefa Neemuchwala, global head of digital health solutions and AI at Medtronic, said in a Facebook live informational session. "It is an intelligent assistant that keeps track of all of your information and has all of your information in one place. Then through Watson technology we use this information to power insights so we can better manage your diabetes so that you can spend more time in range."
The need for new medications is higher than ever, but so is the cost and time to bring them to market. Developing a new drug can cost billions and take as long as 14 years, according to the U.S. Food and Drug Administration. Yet with all that effort, only 8 percent of drugs make it to market, the FDA said. "We need to make smarter decisions about which potential medicines we develop and test," said Abraham Heifets, co-founder of San Francisco-based startup Atomwise. The six-year-old company, a member of our Inception startup incubator program, is working to make that happen by using GPU-accelerated deep learning to predict which molecules are most likely to lead to treatments.
Called IQcast, the feature tells users whether they have a low, medium or high chance of dropping below the target blood glucose range within the next one to four hours. These individual-specific predictions are generated by analyzing data collected through Sugar.IQ app and the Guardian Connect device. The Sugar.IQ app is currently available in the App Store for free download. The FDA-cleared app uses IBM Watson Health's AI and analytics tools to help users see how their glucose levels change during the day, and includes a smart food logging system, motivational insights, a glycemic assistant, a data tracker and a glycemic insights feature. Hypoglycemia -- defined by the American Diabetes Association as a blood glucose level lower than 70 mg/dL -- can lead to symptoms ranging from lightheadedness and lethargy to vision impairment and seizures.
That's how quickly brain damage happen when the cells get no oxygen in a stroke or in some brain injuries. Both can have tragic consequences -- paralysis, memory loss, speech difficulties and even death. But doctors can't start treatment without an initial diagnosis, and that requires reading a CT scan as soon as the test's completed. Unfortunately, that's not what usually happens, said Prashant Warier, co-founder of Qure.ai, a member of our Inception startup accelerator program. "Radiologists typically have a backlog of cases," he said.
News and hype surround the field of radiology with headlines around the world purporting that it will be disrupted overnight. Few companies though really have the evidence to back up these claims. A combination of factors have led to this field being a target for innovators including the expansion of image archiving, the increase of diagnostic image-sharing and the computer-readable DICOM format. These innovative companies are seeking to apply AI, Machine and Deep Learning to this field in the hope of achieving time and cost savings, and to help doctors detect changes such as tumors, hardening of the arteries and provide highly accurate measurements of organs and blood flow. Even though in principal the challenges in this field are ripe for the application of modern technology, there are considerable market barriers new companies must face.